143
Views
8
CrossRef citations to date
0
Altmetric
Original Articles: Research

Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes

, &
Pages 989-993 | Received 06 Sep 2007, Accepted 04 Feb 2008, Published online: 01 Jul 2009

References

  • Matlin A J, Clark F, Smith C W. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6: 386–398
  • Novoyatleva T, Tang Y, Rafalska I, Stamm S. Pre-mRNA missplicing as a cause of human disease. Prog Mol Subcell Biol 2006; 44: 27–46
  • Venables J P. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647–7654
  • Karlsson-Rosenthal C, Millar J B. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006; 16: 285–292
  • Galaktionov K, Lee A K, Eckstein J, Draetta G, Meckler J, Loda M, et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 269: 1575–1577
  • Le Gac G, Esteve P O, Ferec C, Pradhan S. DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1. J Biol Chem 2006; 281: 24161–24170
  • Hernandez S, Hernandez L, Bea S, Pinyol M, Nayach I, Bellosillo B, et al. cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int J Cancer 2000; 89: 148–152
  • Wegener S, Hampe W, Herrmann D, Schaller H C. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol 2000; 79: 810–815
  • Baldin V, Cans C, Superti-Furga G, Ducommun B. Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Oncogene 1997; 14: 2485–2495
  • Ozen M, Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res 2005; 11: 4701–4706
  • Boultwood J, Fidler C, Strickson A J, Watkins F, Gama S, Kearney L, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 2002; 99: 4638–4641
  • List A, Kurtin S, Roe D J, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557
  • Steensma D P, Gibbons R J, Higgs D R. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005; 105: 443–452
  • Chen M S, Hurov J, White L S, Woodford-Thomas T, Piwnica-Worms H. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol Cell Biol 2001; 21: 3853–3861

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.